Nobuyo Tamiya
About
Nobuyo Tamiya is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Nobuyo Tamiya has authored 68 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 29 papers in Molecular Biology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nobuyo Tamiya's work include Lung Cancer Treatments and Mutations (27 papers), Venomous Animal Envenomation and Studies (20 papers) and Ion channel regulation and function (20 papers). Nobuyo Tamiya is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Venomous Animal Envenomation and Studies (20 papers) and Ion channel regulation and function (20 papers). Nobuyo Tamiya collaborates with scholars based in Japan, United Kingdom and Australia. Nobuyo Tamiya's co-authors include S Sato, Hajime Arai, Nobuo Maeda, Koichi Takayama, Tadaaki Yamada, Junji Uchino, Yoshiko Kaneko, Yusuke Chihara, Yuki Katayama and Y. Kikuchi and has published in prestigious journals such as Cancer Research, Biochemical Journal and Journal of Biomechanics.
In The Last Decade
Nobuyo Tamiya
65 papers receiving 1.2k citations
Peers
Nobuyo Tamiya
Hiroko Toda Japan
Brent W. Sutherland Canada
Jacob A. Galán United States
Neal Gutterson United States
Elisabeth Kruse Germany
Yoko Nishikawa Japan
Ichiro Kubota Japan
Daniel L. Riggs United States
Wai‐Ching Hon United Kingdom
C. Tanzarella Italy
Citations per year, relative to Nobuyo Tamiya Nobuyo Tamiya (= 1×)
peers
Hiroko Toda
Countries citing papers authored by Nobuyo Tamiya
Since
Specialization
Citations
This map shows the geographic impact of Nobuyo Tamiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuyo Tamiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuyo Tamiya more than expected).
Fields of papers citing papers by Nobuyo Tamiya
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nobuyo Tamiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuyo Tamiya. The network helps show where Nobuyo Tamiya may publish in the future.
Co-authorship network of co-authors of Nobuyo Tamiya
This figure shows the co-authorship network connecting the top 25 collaborators of Nobuyo Tamiya. A scholar is included among the top collaborators of Nobuyo Tamiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuyo Tamiya. Nobuyo Tamiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Morimoto, Kenji, Tadaaki Yamada, Toshihide Yokoyama, et al.. (2024). Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy. Thoracic Cancer. 15(26). 1882–1888.
2.
Morimoto, Kenji, Tadaaki Yamada, Ryo Sawada, et al.. (2023). Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer. Cancer Immunology Immunotherapy. 72(6). 1699–1707.
3.
Iwasaku, Masahiro, Junji Uchino, Takahiro Yamada, et al.. (2023). Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial. Cancer Medicine. 12(14). 15117–15127.
4.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study. Targeted Oncology. 18(5). 657–665.
5.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study. JTO Clinical and Research Reports. 4(4). 100493–100493.
6.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2023). Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy. Drugs & Aging. 40(6). 563–571.
7.
Hirano, Keita, Takayuki Nakano, Nobuyo Tamiya, et al.. (2023). Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study. Thoracic Cancer. 14(11). 1004–1011.
8.
Morimoto, Kenji, Ryo Sawada, Tadaaki Yamada, et al.. (2022). A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC. JTO Clinical and Research Reports. 3(9). 100388–100388.
9.
Morimoto, Kenji, Tadaaki Yamada, Takayuki Takeda, et al.. (2022). Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. JTO Clinical and Research Reports. 3(7). 100353–100353.
10.
Yamada, Tadaaki, Junji Uchino, Yusuke Chihara, et al.. (2020). Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). Therapeutic Advances in Medical Oncology. 12. 3863542881–3863542881.
11.
Yamada, Tadaaki, Yuki Katayama, Akihiro Yoshimura, et al.. (2019). Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer. Cancer Medicine. 8(4). 1521–1529.
12.
Imabayashi, Tatsuya, Junji Uchino, Akihiro Yoshimura, et al.. (2019). Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers. 11(3). 410–410.
13.
Katayama, Yuki, Tadaaki Yamada, Keiko Tanimura, et al.. (2019). Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer. Thoracic Cancer. 10(3). 526–532.
14.
Nishioka, Naoya, Junji Uchino, Yuki Katayama, et al.. (2019). Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. Journal of Clinical Medicine. 8(4). 450–450.
15.
Yoshimura, Akihiro, Tadaaki Yamada, Takayuki Takeda, et al.. (2019). Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers. 11(3). 365–365.
16.
Katayama, Yuki, Junji Uchino, Yusuke Chihara, et al.. (2019). Tumor Neovascularization and Developments in Therapeutics. Cancers. 11(3). 316–316.
17.
Imabayashi, Tatsuya, Junji Uchino, Keiko Tanimura, et al.. (2019). Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. Cancers. 11(3). 282–282.
18.
Hiranuma, Osamu, Junji Uchino, Tadaaki Yamada, et al.. (2019). Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). Clinical Lung Cancer. 20(3). e402–e406.
19.
Nishioka, Naoya, Tadaaki Yamada, Yuki Katayama, et al.. (2018). Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. Respiratory Medicine Case Reports. 25. 261–263.
20.
Guinea, Michael L., Nobuyo Tamiya, & Harold G. Cogger. (1983). The neurotoxins of the sea snake Laticauda schistorhynchus. Biochemical Journal. 213(1). 39–41.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hiroko Toda Breakdown of academic impact, for papers by Brent W. Sutherland Breakdown of academic impact, for papers by Jacob A. Galán Breakdown of academic impact, for papers by Neal Gutterson Breakdown of academic impact, for papers by Elisabeth Kruse Breakdown of academic impact, for papers by Yoko Nishikawa Breakdown of academic impact, for papers by Ichiro Kubota Breakdown of academic impact, for papers by Daniel L. Riggs Breakdown of academic impact, for papers by Wai‐Ching Hon Breakdown of academic impact, for papers by C. Tanzarella